Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Abigail Shea(Institute of Cancer Research), Alejandra Bruna(Institute of Cancer Research), Daniel Guerrero-Romero(University of Cambridge), Dimitra Georgopoulou(University of Cambridge), Jean Abraham(Cancer Research UK), Louise Grybowicz(Cambridge University Hospitals NHS Foundation Trust), Martin O’Reilly(University of Cambridge), Jonny Lay(University of Cambridge), Sophia Wix(University of Cambridge), Agnese Giovannetti(Agostino Gemelli University Polyclinic), Karen McAdam(Peterborough City Hospital), Elham Esmaeilishirazifard(AstraZeneca (United Kingdom)), Helen Bardwell(University of Cambridge), Raquel Manzano García(University of Cambridge), Yaniv Lubling(University of Cambridge), Giulia Lerda(University of Cambridge), Maurizio Callari(Fondazione IRCCS Istituto Nazionale dei Tumori), Alistair Martin(University of Cambridge), A. Nagano(The Francis Crick Institute), Riccardo Masina(University of Cambridge), Elena Provenzano(University of Cambridge), Steven Kupczak(Cancer Research UK Cambridge Center), Carlos Caldas(Université Libre de Bruxelles), Justine Kane(University of Cambridge), Yi Cheng(University of Cambridge), Wei Cope(Cambridge University Hospitals NHS Foundation Trust), Oscar M. Rueda(University of Cambridge), Lisa Young(University of Cambridge), Wendy Greenwood(University of Cambridge)
Cited by 7
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Lung adenocarcinoma promotion by air pollutants
|Nature|2023|751